Farmacocinética y farmacodinamia de antimicrobianos: a propósito de pacientes con neutropenia y fiebre

Garzón, Javier; M, Sonia Cuervo; R, Julio Gómez; Cortés, Jorge Alberto

doi:10.4067/s0716-10182011000700005

Cited by 6 publications

(7 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These variations were identified because the extracellular fluid (ECF) levels in these patients were different than in healthy patients. Changes in ECF levels affect the plasma concentrations of antibiotics [1,2]. …”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy

Álvarez

Cuervo

Garzón³

et al. 2013

BMC Pharmacol Toxicol

Self Cite

View full text Add to dashboard Cite

IntroductionPatients with febrile neutropenia (FN) exhibit changes in extracellular fluid that may alter the plasma concentrations of beta-lactams and result in therapeutic failure or toxicity. We evaluated the pharmacokinetics of piperacillin/tazobactam in patients with hematological malignancies and FN after receiving chemotherapy at a primary public cancer center.MethodsThis was an open, nonrandomized, observational, descriptive, and prospective study. Samples from 15 patients with hematological malignancies and FN were evaluated after the administration of chemotherapy. Five blood samples were taken from each patient when the antibiotic level was at steady-state 10, 60, 120, 180, and 350 min after each dose. Antibiotic concentrations were measured using gel diffusion with Bacillus subtilis. All study participants provided written informed consent.ResultsWe investigated the pharmacokinetics of piperacillin in 14 patients between the ages of 18 years and 59 years and with a mean absolute neutrophil count of 208 cells per mm3 (standard deviation (SD) ± 603.2). The following pharmacokinetic measurements were obtained: maximum concentration, 94.1–1133 mg/L; minimum concentration, 0.47–37.65 mg/L; volume of distribution, 0.08–0.65 L/kg (mean, 0.34 L/kg); drug clearance (CL), 4.42–27.25 L/h (mean, 9.93 L/h); half-life (t1/2), 0.55–2.65 h (mean, 1.38 h); and area under the curve, 115.12–827.16 mg · h/L.ConclusionPatients with FN after receiving chemotherapy exhibited significant variations in the pharmacokinetic parameters of piperacillin compared with healthy individuals; specifically, FN patients demonstrated an increase in t1/2 and decreased CL.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy

Álvarez

Cuervo

Garzón³

et al. 2013

BMC Pharmacol Toxicol

Self Cite

View full text Add to dashboard Cite

show abstract

“…En el caso de gentamicina, la relación entre su Cmax y la CIM es el parámetro dual que mejor predice su eficacia antimicrobiana [16][17][18] . En función de esto, se recomiendan regímenes de gentamicina en monodosis diaria [15][16][17][18][19][20][21] . El objetivo del presente estudio fue determinar los parámetros FC de gentamicina en RN de término, sin enfermedad crítica, internados en el Servicio de Recién Nacidos del CHPR.…”

Section: Artículo Originalunclassified

Parámetros farmacocinéticos de gentamicina en recién nacidos de término: ¿Es necesario monitorizar en forma sistemática sus concentraciones plasmáticas?

Telechea

Gesuele

Grosso

et al. 2016

Rev. chil. infectol.

View full text Add to dashboard Cite

show abstract

“…Incluso, se encontró que la defervescencia era más temprana en pacientes con 750 mg cada día, con respecto a los que recibían 500 mg: la defervescencia en el primer grupo se alcanzó a los tres días (p = 0,006) 47 . Esto se atribuye al efecto farmacodinámico dependiente de dosis de las quinolonas 32,48 .…”

Section: Fluoroquinolonasunclassified

Duración del tratamiento y administración oral de antimicrobianos en neumonía adquirida en la comunidad

Bernal-Vargas

Cortés

2016

Rev. chil. infectol.

Self Cite

View full text Add to dashboard Cite

Community acquired pneumonia (CAP) is an important cause of morbidity and mortality around the world, with high treatment costs due to hospitalization and complications (adverse events due to medications, antibiotic resistance, healthcare associated infections, etc.). It has been proposed administration of short courses and early switch of intravenous administration to oral therapy to avoid costs and complications. There are recommendations about these topics in national and intemational guidelines, based on clinical trials which do not demónstrate diffe-rences in mortality and complications when there is an early change from intravenous administration to the oral route. There are no statistically significant differences in safety and resolution of the disease when short and long treatment schemes were compared. In this review we present the most important guidelines and clinical studies, taking into account the pharmacological differences between different medications. It is considered that early switch from intravenous to oral administration route and use of short cycles in CAP is safe and brings benefits to patients and institutions.

show abstract

Farmacocinética y farmacodinamia de antimicrobianos: a propósito de pacientes con neutropenia y fiebre

Cited by 6 publications

References 59 publications

Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy

Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy

Parámetros farmacocinéticos de gentamicina en recién nacidos de término: ¿Es necesario monitorizar en forma sistemática sus concentraciones plasmáticas?

Duración del tratamiento y administración oral de antimicrobianos en neumonía adquirida en la comunidad

Contact Info

Product

Resources

About